Potent <i>N</i>-(1,3-Thiazol-2-yl)pyridin-2-amine Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors with Excellent Pharmacokinetics and Low Affinity for the hERG Ion Channel
Mark T. Bilodeau(Kettering University), George D. Hartman(Joint BioEnergy Institute), David Heimbrook(United States Military Academy), Raju Subramanian(Gilead Sciences (United States)), Kenneth A. Thomas(United States Military Academy), Jennifer M. Shipman(Johns Hopkins University), Nancy E. Kohl(United States Military Academy), Rosemary C. McFall(United States Military Academy), Cynthia Miller‐Stein(United States Military Academy), Keith Rickert(United States Military Academy), Timothy J. Koester(United States Military Academy), Laura Sepp‐Lorenzino(Intellia Therapeutics (United States)), Kathleen Coll(United States Military Academy), W. Wayt Gibbs(United States Military Academy), Carolyn Buser‐Doepner(GlaxoSmithKline (United States)), Sean Yu(United States Military Academy), Joseph J. Lynch(United States Military Academy), Adrienne E. Balitza(United States Military Academy), Leonard D. Rodman(United States Military Academy), Peter J. Manley(United States Military Academy), Debra A. McLoughlin(United States Military Academy), Bradley K. Wong(United States Military Academy), William R. Huckle(United States Military Academy), Christine Fernandes(United States Military Academy), Xianzhi Mao(United States Military Academy)
Cited by 60
Related Papers
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k
The promise and peril of chemical probes
|Nature Chemical Biology|2015|848
Total Synthesis of Spirotryprostatin A, Leading to the Discovery of Some Biologically Promising Analogues
|Journal of the American Chemical Society|1999|463
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
|Cancer Immunology Research|2015|440